Two different regimens of Nolvadex in preventing gynecomastia induced by Casodex 150 mg in patients with prostate cancer
Study identifier:7054IT/0003
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A comparative trial of the efficacy of two different Nolvadex (NDX) dosing and scheduling regimens in preventing gynecomastia induced by Casodex (CDX) 150 monotherapy in prostate cancer patients. An open, multicenter, phase III trial.
Medical condition
prostate cancer
Phase
Phase 3
Healthy volunteers
No
Study drug
Bicalutamide, Tamoxifen
Sex
Male
Actual Enrollment
180
Study type
Interventional
Age
18 Years - 75 Years
Date
Study Start Date: 01 Dec 2003
Primary Completion Date: 01 Oct 2007
Study Completion Date: 01 Oct 2007
Study design
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Verification:
Verified 01 Jan 2011 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
Astra Zeneca
AstraZeneca
